Greenstone LLC Introduces 12 Generic Products To Date in 2011
Peapack, NJ; October 2011 — Through just the first nine months of 2011, Greenstone
LLC, the generic pharmaceutical subsidiary of Pfizer Inc., has expanded its line of
product offerings by introducing 12 additional generics, bringing the company’s current
portfolio to more than 80 generic medicines.
Amongst this group of 12 new products are the following:
- Diphenoxylate Hydrochloride and Atropine Sulfate Tablets
- Exemestane Tablets
- Famciclovir Tablets
- Gabapentin Oral Solution
- Galantamine Tablets
- Latanoprost Sterile Ophthalmic Solution
- Voriconazole Tablets
As anticipated, the portfolio of products offered by Greenstone continues to expand, with
a combination of ANDAs and Authorized Generics.
Each product in the Greenstone portfolio is supported by the company’s long-standing
commitment to quality, reliable manufacturing, and customer-centric attention.
Back to Press Releases
About Greenstone
Greenstone LLC, established in 1993, is a wholly owned subsidiary of Pfizer Inc,
one of the largest pharmaceutical companies in the world. Greenstone, which focuses
on customer service, markets a broad line of quality Authorized Generics —
along with an expanding line of ANDA (Abbreviated New Drug Application) generics.
Greenstone Authorized Generics, well known for having the same physical characteristics
as the innovators' brands, are supported by state-of-the-art distribution and operations
services. Greenstone is working with numerous brand pharmaceutical companies to
assist in their "post-exclusivity" planning, with a focus on Authorized Generics.
The company offers a robust product pipeline that highlights quality generic equivalents
to some of the best-selling branded pharmaceuticals. Greenstone LLC will continue
to offer numerous future product opportunities for pharmacies and its trade partners.